Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: pocotrader who wrote (1309669)	7/27/2021 11:53:24 AM
From: Winfastorlose	3 Recommendations Recommended By Broken_Clock Maple MAGA Mick Mørmøny Read Replies (1) \| Respond to of 1583492

That blog was written by an idiot, offering no proof to back his conclusions. Is that your blog?

To: pocotrader who wrote (1309669)	7/27/2021 12:37:05 PM
From: Broken_Clock	Read Replies (1) \| Respond to of 1583492

"only two of the studies I found" a guy with a negative viewpoint trying to undermine HG must have looked really hard, right? Apparently he missed this on PubMed...took me what? 2 minutes? . 2020 Nov;38:100776. doi: 10.1016/j.nmni.2020.100776. Epub 2020 Oct 5. Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review C Prodromos 1 , T Rumschlag 2 Affiliations PMID: 33042552 PMCID: PMC7534595 DOI: 10.1016/j.nmni.2020.100776 Free PMC article Abstract Hydroxychloroquine (HCQ) has shown efficacy against coronavirus disease 2019 (COVID-19) in some but not all studies. We hypothesized that a systematic review would show HCQ to be effective against COVID-19, more effective when provided earlier, not associated with worsening disease and safe. We searched PubMed, Cochrane, Embase, Google Scholar and Google for all reports on HCQ as a treatment for COVID-19 patients. This included preprints and preliminary reports on larger COVID-19 studies. We examined the studies for efficacy, time of administration and safety. HCQ was found to be consistently effective against COVID-19 when provided early in the outpatient setting. It was also found to be overall effective in inpatient studies. No unbiased study found worse outcomes with HCQ use. No mortality or serious safety adverse events were found. HCQ is consistently effective against COVID-19 when provided early in the outpatient setting, it is overall effective against COVID-19, it has not produced worsening of disease and it is safe.